NICE defines rapid tranquilisation (RT) as the use of medication to calm/lightly sedate the service user, reduce the risk to self and/or others and achieve an optimal reduction in agitation and aggression, thereby allowing a thorough psychiatric evaluation to take place and allowing comprehension and response to spoken messages throughout the intervention. The aim should be to maintain the service user in as calm a state as possible whilst being able to maintain communication with them. It is recognised that rapid tranquilisation may lead to deep sedation/anaesthesia, although this is not the overt intention.¹

Always consider any antecedents to the the acute situation - has the situation been exacerbated by poor communication, lack of privacy, overcrowding, boredom, long waiting times or lack of information - will skilled interviewing techniques (and other interventions, e.g. de-escalation) negate the need for RT?

NICE recommend that after a rapid tranquilisation episode, the patient should be invited to record their own experience of the incident.²

Initial assessment

This should ideally include:

• Full history - from as many sources as possible.
• Legal status - is patient already under the Mental Capacity Act (MCA)?
• If patient is already on a psychiatric ward (informally or under section 5(2)), RT treatment can be given under common law.
• Mental state examination.
• Previous psychiatric history.
• Full medication history - including alcohol and substance abuse.
• Physical examination (if safe to do so).
• Recent drug screen (if available).

Always think of organic causes (particularly if fluctuating levels of consciousness, disorientation, visual hallucinations) or any previous head injury.

Legal issues

• RT should be humane, ethical, legal and clinically effective.
• Consider the presence of any advance directives.
• Primary concern in violent situations should be for the safety of all. Decisions made in good faith by medical staff in the acute situation, taken to avert serious risk, can be sanctioned by common law without recourse to the Mental Capacity Act (MCA). All treatment should be reasonable and proportionate. Where possible, treatment without consent should be under one of the treatment sections of the MCA (usually section 3).

Assess risks

Risks are increased in children, frail elderly, pregnancy, Lewy body dementia, or by concurrent medical illness.

These risks are:

• Loss of consciousness
• Airway obstruction
• Respiratory depression ± arrest
• Hypotension or cardiovascular collapse
• Cardiac Arrest
• Seizure
• Extrapyramidal side-effects (EPSE) or neuroleptic malignant syndrome

Exclude medical contraindications to RT (e.g. cardiac disease or respiratory disorders) and ensure facilities for basic CPR and flumazenil are available.

Oral regimens¹

• Oral medication is preferred to parenteral drugs whenever possible.
• NICE suggests lorazepam, olanzapine or haloperidol (if using haloperidol, consider anticholinergic).
• Do not use "drug cocktails" and keep to within manufacturers' recommended doses (use minimum effective dose) whenever possible. NICE accept that there may be rare occasions when the dosage range recommended by the manufacturer may need to be exceeded. In this situation a risk-benefit analysis should be made and recorded. More intensive monitoring will then be required than if the dosage had been within the recommended range.
• Lorazepam should be considered first for non-psychotic behavioural disturbance - oral if possible but intramuscular if necessary.
• Behavioural disturbance in the context of psychosis should be treated with lorazepam combined with an anti-psychotic.
• Olanzapine (and risperidone) should be avoided in patients with dementia, due to an increased risk of stroke and death.

Parenteral regimens¹

• The intramuscular route is safer than the intravenous route.
• Oral therapy should be commenced as soon as feasible.
• Never mix lorazepam with other drugs in the same syringe. Using olanzapine with lorazepam concurrently is not recommended. Ideally give antimuscarinic drug (e.g. procyclidine) if haloperidol is given.³

Chart for rapid tranquilisation

Monitoring

• BP/pulse/respiratory rate every 5 minutes, temperature every 30 minutes and look for evidence of dystonia.
• Transfer (accompanied by staff) only when patient has been stable for at least 30 minutes (calm and cardiovascular and respiratory observations stable).

Documentation

Ensure at least the following minimum is recorded:¹

Reasons for using RT

• Legal situation (i.e. which part of MHA used)
• Physical assessment - any medical hazards recognised
• Patient's diagnosis
• Drugs given - in what sequence and dosage
• Outcome
• Monitoring chart and ongoing plan

Debrief

Discuss as a significant event - could need for RT have been anticipated and prevented? Discuss patient's account if available.